Otilimab

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Arthritis, RheumatoidSevere Acute Respiratory Syndrome

Phase 1

A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

WithdrawnNCT05304130

GlaxoSmithKlineArthritis, Rheumatoid

Start: 2023-02-08End: 2023-05-04Updated: 2023-01-26

Phase 2

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

CompletedNCT04376684

GlaxoSmithKlineSevere Acute Respiratory Syndrome

Start: 2020-05-28End: 2021-08-16Updated: 2024-09-23

Related Papers

Fibroblast activity biomarkers are associated with mortality in severe COVID-19: a post-hoc analysis of a phase 2 clinical trial

Respiratory Research2026-06-25

Serum collagen biomarkers are related to fatal outcome in patients with severe COVID-19 in a Phase II clinical trial

2023-09-091 citations

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

European Respiratory Journal2022-10-1342 citations

Late Breaking Abstract - Enhanced immune activation pathways enriched in patients =70 years with severe COVID-19

2021-09-05